Last reviewed · How we verify
Aurexis®
Selective serotonin reuptake inhibitor
Selective serotonin reuptake inhibitor Used for Major depressive disorder.
At a glance
| Generic name | Aurexis® |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | SSRI |
| Target | Serotonin transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 2 |
Mechanism of action
Aurexis is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain, which helps to improve mood and reduce symptoms of depression.
Approved indications
- Major depressive disorder
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB) (PHASE2)
- Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aurexis® CI brief — competitive landscape report
- Aurexis® updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI